pioneer 8 semaglutide Oral versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial The Importance of Patient-Reported Outcomes

Wegovy (semaglutide) is a prescription weight loss drug classified as a glucagon-like peptide-1 (GLP-1) agonist thats administered once weekly by subcutaneous injection (injection under the skin)

(download DOCX Summary of LEADER model, including full details of the baseline variables considered in the model

Role of resveratrol supplementation in regulation of glucose hemostasis, inflammation and oxidative stress in patients with diabetes mellitus type 2: A randomized, placebo-controlled trial

Using the GLP3Planner calculator to log your injection day helps maintain a consistent weekly schedule as you titrate through the dose steps

We recognise that getting the healthcare assistance you need can be difficult